$4.53 Billion in Sales Expected for Teva Pharmaceutical Industries Ltd (TEVA) This Quarter

Equities analysts forecast that Teva Pharmaceutical Industries Ltd (NYSE:TEVA) will announce $4.53 billion in sales for the current quarter, Zacks Investment Research reports. Seven analysts have issued estimates for Teva Pharmaceutical Industries’ earnings. The lowest sales estimate is $4.41 billion and the highest is $4.76 billion. Teva Pharmaceutical Industries reported sales of $5.46 billion in the same quarter last year, which indicates a negative year over year growth rate of 17%. The company is scheduled to report its next quarterly earnings results on Thursday, February 14th.

On average, analysts expect that Teva Pharmaceutical Industries will report full-year sales of $18.85 billion for the current financial year, with estimates ranging from $18.71 billion to $19.05 billion. For the next fiscal year, analysts forecast that the company will post sales of $17.89 billion, with estimates ranging from $17.22 billion to $18.15 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that cover Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Thursday, November 1st. The company reported $0.64 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.53 by $0.11. Teva Pharmaceutical Industries had a negative net margin of 54.67% and a positive return on equity of 21.83%. The firm had revenue of $4.53 billion during the quarter, compared to analyst estimates of $4.54 billion. During the same quarter in the prior year, the business earned $1.00 earnings per share. Teva Pharmaceutical Industries’s revenue for the quarter was down 19.4% on a year-over-year basis.

TEVA has been the subject of several research reports. Mizuho reiterated a “buy” rating and set a $28.00 price objective on shares of Teva Pharmaceutical Industries in a research report on Thursday, August 16th. ValuEngine upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Tuesday, August 7th. Goldman Sachs Group upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “conviction-buy” rating and set a $30.00 price objective for the company in a research report on Monday, October 1st. Morgan Stanley increased their price objective on shares of Teva Pharmaceutical Industries from $19.00 to $20.00 and gave the company an “equal weight” rating in a research report on Friday, August 3rd. Finally, Cantor Fitzgerald reiterated a “hold” rating and set a $25.00 price objective on shares of Teva Pharmaceutical Industries in a research report on Thursday, August 16th. Four analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $21.58.

TEVA stock traded down $0.39 during trading on Monday, hitting $23.45. 6,637,061 shares of the company’s stock traded hands, compared to its average volume of 10,918,274. Teva Pharmaceutical Industries has a 52 week low of $11.44 and a 52 week high of $25.96. The company has a quick ratio of 0.61, a current ratio of 0.94 and a debt-to-equity ratio of 1.75. The firm has a market capitalization of $24.13 billion, a P/E ratio of 7.39, a price-to-earnings-growth ratio of 7.28 and a beta of 0.77.

In other news, VP Richard Daniell sold 2,488 shares of the firm’s stock in a transaction dated Tuesday, September 18th. The shares were sold at an average price of $23.69, for a total value of $58,940.72. Following the completion of the sale, the vice president now owns 2,488 shares in the company, valued at approximately $58,940.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Deborah A. Griffin sold 2,376 shares of the firm’s stock in a transaction dated Tuesday, September 18th. The stock was sold at an average price of $23.71, for a total transaction of $56,334.96. Following the completion of the sale, the insider now owns 2,376 shares of the company’s stock, valued at approximately $56,334.96. The disclosure for this sale can be found here. Insiders sold a total of 6,531 shares of company stock valued at $152,749 in the last 90 days. Company insiders own 0.43% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the company. CIBC World Markets Inc. increased its stake in Teva Pharmaceutical Industries by 9.6% in the 3rd quarter. CIBC World Markets Inc. now owns 536,143 shares of the company’s stock worth $11,549,000 after buying an additional 46,887 shares during the period. FMR LLC increased its stake in Teva Pharmaceutical Industries by 19.1% in the 3rd quarter. FMR LLC now owns 24,481,936 shares of the company’s stock worth $527,341,000 after buying an additional 3,921,785 shares during the period. Polaris Capital Management LLC increased its stake in Teva Pharmaceutical Industries by 9.0% in the 3rd quarter. Polaris Capital Management LLC now owns 9,911,038 shares of the company’s stock worth $213,484,000 after buying an additional 817,964 shares during the period. Fosun International Ltd increased its stake in Teva Pharmaceutical Industries by 36.5% in the 3rd quarter. Fosun International Ltd now owns 43,000 shares of the company’s stock worth $909,000 after buying an additional 11,500 shares during the period. Finally, Janus Henderson Group PLC increased its stake in Teva Pharmaceutical Industries by 11.4% in the 3rd quarter. Janus Henderson Group PLC now owns 141,421 shares of the company’s stock worth $3,047,000 after buying an additional 14,500 shares during the period. Hedge funds and other institutional investors own 65.10% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

See Also: Outstanding Shares

Get a free copy of the Zacks research report on Teva Pharmaceutical Industries (TEVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply